Having trouble accessing articles? Reset your cache.

Budesonide MMX meets Phase III endpoint

Santarus Inc. (NASDAQ:SNTS) and Cosmo Pharmaceuticals S.p.A. (SIX:COPN) said the higher of two doses of budesonide MMX met the primary endpoint

Read the full 218 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE